- Home
- CYRX vs ERAS Comparison
CYRX vs ERAS Comparison
Compare CYRX & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYRX | ERAS |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 438.7M | 927.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CYRX | ERAS |
|---|---|---|
| Price | $9.37 | $3.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $12.83 | $3.71 |
| AVG Volume (30 Days) | 594.0K | ★ 2.0M |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $243,795,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.26 | N/A |
| P/E Ratio | $7.44 | ★ N/A |
| Revenue Growth | ★ 41.27 | N/A |
| 52 Week Low | $4.58 | $1.01 |
| 52 Week High | $11.44 | $3.62 |
Technical Indicators
Market Signals| Indicator | CYRX | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 49.73 | 71.90 |
| Support Level | $9.08 | $3.15 |
| Resistance Level | $10.30 | $3.48 |
| Average True Range (ATR) | 0.46 | 0.22 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 42.94 | 99.81 |
Price Performance
Historical ComparisonAbout CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.